Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from Roth Mkm

Roth Mkm reissued their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a report issued on Tuesday morning,Benzinga reports. Roth Mkm currently has a $7.00 target price on the stock.

Several other equities analysts have also recently issued reports on GANX. Roth Capital upgraded Gain Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research report on Monday, November 25th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $7.25.

Gain Therapeutics Price Performance

Shares of GANX opened at $1.59 on Tuesday. The firm’s 50 day moving average price is $2.03 and its 200 day moving average price is $1.61. The company has a market cap of $42.17 million, a P/E ratio of -1.45 and a beta of 0.21. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. Gain Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $5.33.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of GANX. Renaissance Technologies LLC boosted its stake in Gain Therapeutics by 154.2% in the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after acquiring an additional 72,000 shares in the last quarter. Warberg Asset Management LLC purchased a new stake in Gain Therapeutics in the second quarter valued at approximately $66,000. Hohimer Wealth Management LLC acquired a new stake in shares of Gain Therapeutics in the second quarter valued at approximately $422,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Gain Therapeutics by 48.0% in the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after acquiring an additional 88,236 shares during the period. Institutional investors and hedge funds own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.